Bad Berka

• MK-0616-013 Not authorised
  2022-502777-42-00 5 Hypercholesterolemia
• Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros … Pending
  2024-518013-25-00 4 Idiopathic Pulmonary Fibrosis
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm … Recruiting
  2024-515853-48-00 5 2025-09-05 advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Recruiting
  2023-504904-26-00 5 2025-04-07 Progressive Pulmonary Fibrosis
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB
• BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) with Chemotherapy vs Atezolizumab with Chemotherapy as First-line Therapy in Part … Ended recruitment
  2024-515740-23-00 5 2025-03-25 Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• Extension Study of Inhaled Treprostinil in Subjects with Fibrotic Lung Disease Ended recruitment
  2023-504471-25-00 5 2024-03-01 Fibrotic Lung Disease
• Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended recruitment
  2023-507263-19-00 5 2020-12-23 Advanced Non-Small Cell Lung Cancer
• A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended recruitment
  2023-506576-27-00 5 2020-09-30 EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended recruitment
  2023-504820-24-00 5 2018-03-21 Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
• Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE) Ended recruitment
  2023-510444-21-00 5 2017-11-24 Neuroendocrine tumours of gastroenteric or pancreatic origin
• CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3 Ended
  2024-510863-50-00 4 2024-08-30 Neuroendocrine Neoplasia Neuroendocrine Tumor
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia

Showing 1–24 of 28 trials